Tuesday, Centogene N.V. (CNTG) extended its partnership with Takeda Pharmaceuticals Co. Ltd. (TAK) to diagnose patients with Lysosomal Storage Disorders or LSDs. The financial details of the agreement were not disclosed.
The agreement allows Centogene to offer Takeda access to genomic and multiomic testing worldwide, aiming to improve patient access to fast and accurate LSD diagnostics, covering conditions like Fabry disease, Gaucher disease, and Hunter syndrome.
Initially, in January 2015, Centogene partnered with Shire Pharmaceuticals, later acquired by Takeda in 2019, to provide diagnostic testing for early detection of rare genetic diseases.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.